Observational analysis demonstrates IRF1 promotes bone formation and reduces osteoporosis in mesenchymal stem cells, indicating its potential as a therapeutic target.
This study suggested that overexpression of Irf1 promotes osteogenic differentiation of BMSCs and has a therapeutic effect on osteoporosis. IRF1 could play dual roles as a biomarker for bone formation and a target for osteoporosis treatment.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: